Posted by Michael Wonder on 03 Mar 2025
Latigo Biotherapeutics granted FDA fast track designation for LTG-001, potential best in class Nav1.8 inhibitor for the non-opioid treatment of acute pain
3 March 2025 - LTG-001 demonstrated favourable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial.
Latigo Biotherapeutics today announced the US FDA has granted fast track designation to LTG-001, the company's oral, investigational selective Nav1.8 inhibitor for the treatment of acute pain.
